[研Ta究bl报e_告TitlRe]esearchReport19Jun2024Healthcare亚盛医药第三代BCR-ABL抑制剂奥雷巴替尼授权武田制药，同时获得股权投资AscentagePharmahaslicenseditsthird-generationBCR-ABLinhibitor,Olverembatinib...
